Annexon Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
ANNX$4.21-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Cost | Capital | Income (Loss) | Deficit | Equity | |
| Balances as of December 31, 2022 | 47,722,995 | $48 | $669,780 | $(372) | $(438,262) | $231,194 |
| Exercise of stock options | 76,888 | — | 145 | — | — | 145 |
| Exercise of pre-funded warrants | 2,582,557 | 3 | (3) | — | — | — |
| Issuance of common stock to a related party, net of issuance costs of $525 | 2,646,458 | 2 | 17,468 | — | — | 17,470 |
| Issuance of common stock and pre- funded warrants, net of issuance cost of $8,014 | 25,035,000 | 25 | 116,977 | — | — | 117,002 |
| Issuance of common stock per Employee Stock Purchase Plan purchase | 133,105 | — | 479 | — | — | 479 |
| Restricted stock vested in the period | 172,096 | — | — | — | — | — |
| Stock-based compensation | — | — | 18,183 | — | — | 18,183 |
| Other comprehensive income | — | — | — | 320 | — | 320 |
| Net loss | — | — | — | — | (134,237) | (134,237) |
| Balances as of December 31, 2023 | 78,369,099 | 78 | 823,029 | (52) | (572,499) | 250,556 |
| Exercise of stock options | 382,122 | — | 1,232 | — | — | 1,232 |
| Exercise of pre-funded warrants | 8,947,923 | 9 | (9) | — | — | — |
| Exercise of common warrants | 19,901 | — | — | — | — | — |
| Issuance of common stock, net of issuance costs of $1,528 | 8,326,067 | 8 | 42,835 | — | — | 42,843 |
| Issuance of common stock and pre-funded warrants, net of issuance costs $8,183 | 13,001,120 | 13 | 116,804 | — | — | 116,817 |
| Issuance of common stock per Employee Stock Purchase Plan purchase | 138,147 | 1 | 361 | — | — | 362 |
| Restricted stock vested in the period | 197,177 | — | — | — | — | — |
| Stock-based compensation | — | — | 19,433 | — | — | 19,433 |
| Other comprehensive income | — | — | — | 62 | — | 62 |
| Net loss | — | — | — | — | (138,200) | (138,200) |
| Balances as of December 31, 2024 | 109,381,556 | $109 | $1,003,685 | $10 | $(710,699) | $293,105 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.